[
  {
    "ts": "2025-09-18T20:40:29+00:00",
    "headline": "Is CVS Health a Defensive Pick Among the Best Performing in 2025 Dividend Stocks?",
    "summary": "CVS Health Corporation (NYSE:CVS) is included among the 15 Best Performing Dividend Stocks So Far in 2025. CVS Health Corporation (NYSE:CVS) is an American multinational healthcare company. It has grown far beyond being just a pharmacy chain. Alongside filling prescriptions, the company runs in-store clinics that provide services such as lab tests, health screenings, vaccinations, […]",
    "url": "https://finance.yahoo.com/news/cvs-health-defensive-pick-among-204029874.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "edf9940d-6941-327f-aa33-e550af9f7c1e",
      "content": {
        "id": "edf9940d-6941-327f-aa33-e550af9f7c1e",
        "contentType": "STORY",
        "title": "Is CVS Health a Defensive Pick Among the Best Performing in 2025 Dividend Stocks?",
        "description": "",
        "summary": "CVS Health Corporation (NYSE:CVS) is included among the 15 Best Performing Dividend Stocks So Far in 2025. CVS Health Corporation (NYSE:CVS) is an American multinational healthcare company. It has grown far beyond being just a pharmacy chain. Alongside filling prescriptions, the company runs in-store clinics that provide services such as lab tests, health screenings, vaccinations, […]",
        "pubDate": "2025-09-18T20:40:29Z",
        "displayTime": "2025-09-18T20:40:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4e33e0d1a07889115aefcb74e0ea299f",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is CVS Health a Defensive Pick Among the Best Performing in 2025 Dividend Stocks?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yrDm7iyVNAagx0oOilifnQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4e33e0d1a07889115aefcb74e0ea299f.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q.L_4QVhEk8dUSgrDa_Iag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4e33e0d1a07889115aefcb74e0ea299f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cvs-health-defensive-pick-among-204029874.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cvs-health-defensive-pick-among-204029874.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-18T12:37:00+00:00",
    "headline": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
    "summary": "Amid a flurry of news out of the world’s leading weight-loss drugmakers  Novo Nordisk  and  Eli Lilly  this week, Berenberg broke with the common Wall Street view that Lilly is the better obesity play.  Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy from Hold Tuesday.  The analysts see opportunities for new CEO Maziar Mike Doustdar to positively surprise investors, even as some hurdles remain.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-glp1-drugs-505b23e8?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b6a84bcc-ea57-36a3-9f15-396a96d5f2aa",
      "content": {
        "id": "b6a84bcc-ea57-36a3-9f15-396a96d5f2aa",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
        "description": "",
        "summary": "Amid a flurry of news out of the world’s leading weight-loss drugmakers  Novo Nordisk  and  Eli Lilly  this week, Berenberg broke with the common Wall Street view that Lilly is the better obesity play.  Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy from Hold Tuesday.  The analysts see opportunities for new CEO Maziar Mike Doustdar to positively surprise investors, even as some hurdles remain.",
        "pubDate": "2025-09-18T12:37:00Z",
        "displayTime": "2025-09-18T12:37:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b6a84bcc-ea57-36a3-9f15-396a96d5f2aa/novo-nordisk-stock-is-a.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/019f884130a6e200476be84a3ab8457a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZSFoYvCd8e.k8vl3TWvLsg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/019f884130a6e200476be84a3ab8457a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gOhtizi3tDMbrEr9yGeQEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/019f884130a6e200476be84a3ab8457a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-glp1-drugs-505b23e8?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]